Berobenatide (PF-08653944) for overweight or obesity in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 interventional trial will compare berobenatide to placebo in about 950 adults with overweight or obesity, including many with type 2 diabetes. Participants receive injections under the skin and will spend about 20 months in the study with around 15 on-site visits and 2 remote visits. The aim is to determine the safety and effectiveness of berobenatide for weight loss and its impact on related metabolic conditions. Key eligibility requires adults with BMI >=30 or BMI 27-29.9 plus obesity-related comorbidities; certain diabetes and medical history exclusions apply. The study is sponsored by Pfizer and conducted at multiple sites in California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged ≥18 years.
* BMI of: ≥30 kg/m2 or ≥27.0 kg/m2 to \<30.0 kg/m2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.

Exclusion Criteria:

* Have a self-reported body weight change greater than 5% within 90 days prior to Screening.
* Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.
* History of acute or chronic pancreatitis.
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).

Where it's running

• San Fernando Valley Health Institute
  Canoga Park, California, United States Recruiting
• Headlands Research California, LLC
  Escondido, California, United States Recruiting
• ImmuniMet, LLC
  Modesto, California, United States Recruiting
• Clinical Trials Research
  Sacramento, California, United States Recruiting
• University Clinical Investigators, Inc.
  Tustin, California, United States Recruiting
• Diablo Clinical Research, Inc.
  Walnut Creek, California, United States Recruiting

+30 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching to a monthly dose of Berobenatide to help keep weight off after weight loss with semaglutide or tirzepatide

  This study tests whether switching to a monthly berobenatide shot can help adults who have overweight or obesity and have already lost weight using semaglutide or tirzepatide to keep the weight off.

  Recruiting at 18 sites Phase 3 Pfizer · Birmingham, Alabama and 25 other locations · NCT07845500

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.